Most global pharma and biotech programs lose 9–18 months and USD 5–25 million when navigating India without continuous, on-ground oversight.
The result is often a cascade: Form 483 → Warning Letter → Import Alert → Program Termination.
The Aventiq Governance Framework™ was built to prevent this outcome.
A structured, five-pillar governance model, reinforced by AI-enabled intelligence and continuous human oversight, designed to de-risk high-complexity programs including:
Aventiq Bio combines AI-driven intelligence with 20+ years of CRO/CDMO leadership to deliver repeatable outcomes.
Evaluates 150+ vetted CRO/CDMOs across 50+ parameters including regulatory history,
containment, data integrity, capacity, and culture.
Identifies failure points that typically appear only after tech transfer.
You know the risks before capital is committed.
Data-driven alignment of modality, scale, and regulatory pathway.
No long RFP cycles. No unqualified site visits.
Faster decisions, higher confidence, no wasted quarters.
Including ADC conjugation, viral vector production, HPAPI containment, and biologics scale-up.
First-time PPQ success and globally defensible data.
Quarterly audits, live risk monitoring, and crisis response.
AI-supported trend analysis flags deviations months before failure.
Predictability after the contract is signed-not just before.
Your science deserves an unbiased guardian.
In a landscape where many "consultants" accept referral fees from vendors, Aventiq Bio stands alone.
We never accept kickbacks or "incentives" from CROs/CDMOs.
We own no labs, ensuring our technical audits are 100% objective.
We are your scientific proxy on the ground, ensuring your Indian operations meet FDA/EMA expectations-not just local standards.
Our only mandate is your regulatory success
and asset protection.